Article Sidebar
Downloads
Metrics
Main Article Content
Abstract
Intravenous iron supplementation with carboxymaltose represents a new strategy for the treatment of iron deficiency states, with the advantage of administering in a single dose a high amount of iron element, and avoiding side effects such as hypersensitivity. However, hypophosphatemia, a side effect associated with the chronic use of intravenous ferric preparations with carboxymaltose, represents an emerging entity and a new etiology of hypophosphatemia that requires diagnostic suspicion, particularly in patients who are not receiving chronic therapies with this ferric preparation. We present the case of a patient with hypophosphatemia, without a clear cause to justify it, in whom the administration a week before of a punctual dose of carboxymaltose was verified.
Keywords
Article Details
Copyright (c) 2023 Manuel Heras-Benito, Carmen Muñoz-Muñiz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Author copyright notice
© Authors grant the publisher the non-exclusive licence to publish the work and consent to its use and distribution under the Creative Commons Attribution - NonCommercial 4.0 International (CC BY-NC 4.0) licence. Read the licensing information and the legal text here. This must be expressly stated wherever necessary.
References
- Bazeley J W, Wish JB. Recent and emerging therapies for iron deficiency in anemia of CKD: A review. Am J Kidney Dis 2022;79:868-76. DOI: https://doi.org/10.1053/j.ajkd.2021.09.017
- Sánchez González R, Ternavasio de la Vega HG, Moralejo Alonso L, Inés Revuelta S, Fuertes Martín A. Hipofosfatemia asociada a la administración de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente. Med Clin 2015;145:108-11. DOI: https://doi.org/10.1016/j.medcli.2014.10.016
- Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther 2021;38:3531-49. DOI: https://doi.org/10.1007/s12325-021-01770-2
- Tebben PJ. Hypophosphatemia: a practical guide to evaluation and management. Endocrine Practice 2022;28:1091-99. DOI: https://doi.org/10.1016/j.eprac.2022.07.005
- González Hidalgo V, Morán López JM. Severe hypophosphatemia secondary to chronic treatment with endovenous ferric carboxymaltose. Endocrinología, Diabetes y Nutrición 2022;69:646-7. DOI: https://doi.org/10.1016/j.endien.2021.09.002
References
Bazeley J W, Wish JB. Recent and emerging therapies for iron deficiency in anemia of CKD: A review. Am J Kidney Dis 2022;79:868-76. DOI: https://doi.org/10.1053/j.ajkd.2021.09.017
Sánchez González R, Ternavasio de la Vega HG, Moralejo Alonso L, Inés Revuelta S, Fuertes Martín A. Hipofosfatemia asociada a la administración de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente. Med Clin 2015;145:108-11. DOI: https://doi.org/10.1016/j.medcli.2014.10.016
Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther 2021;38:3531-49. DOI: https://doi.org/10.1007/s12325-021-01770-2
Tebben PJ. Hypophosphatemia: a practical guide to evaluation and management. Endocrine Practice 2022;28:1091-99. DOI: https://doi.org/10.1016/j.eprac.2022.07.005
González Hidalgo V, Morán López JM. Severe hypophosphatemia secondary to chronic treatment with endovenous ferric carboxymaltose. Endocrinología, Diabetes y Nutrición 2022;69:646-7. DOI: https://doi.org/10.1016/j.endien.2021.09.002